MUSK and myasthenia gravis: Regarding MuSK+ MG, while there is a lack of data from clinical trials, numerous observational studies have reported that this subclass of patients exhibits a superior (Beecher et al., 2018; Choi et al., 2019; Litchman et al., 2020; Caballero-Ávila et al., 2022; Heckmann, 2022) and more rapid (Stathopoulos et al., 2017; Castiglione et al., 2022) therapeutic response compared to those with AChR+ MG.